Notifications
Back

Pipeline-3

Rare diseases and cancer
with unmet medical needs

SHIFTBIO’s pipeline is aiming to cure orphan diseases and cancer. 

Candidate

SBI-101

[SIRP-Exo]

Indication

Immunotherapy resistant
solid tumor

Discovery

Pre-clinical

Candidate

SBI-102

[SIRP-Exo, MSC]

Indication

NASH with liver fibrosis
Acute Liver Failure

Discovery

Pre-clinical

Candidate

SBI-103

[EGF-Exo]

Indication

Undisclosed

Rights

Discovery

Pre-clinical

Candidate

SBI-104

[Apelin-Exo]

Indication

Pulmonary

arterial hypertension

Rights

Discovery

Pre-clinical

Candidate

SBI-205

[Exo-HIF1α]

Indication

Liver damage

Rights

Discovery

Pre-clinical

Candidate

SBI-306

[RSFV-Exo-UP]

Indication

Immunotherapy resistant
solid tumor

Rights

Discovery

Pre-clinical

Candidate

SBI-407

[Fc-Exo, MSC]

Indication

Undisclosed

Rights

Discovery

Pre-clinical

Candidate

SBI-508
 [Ag-Exo]

Indication

Immunotherapy resistant
solid tumor

Rights


Discovery

Pre-clinical

Candidate

SBI-609, LGP-S01

[ImmuNano]

Indication

Undisclosed

Rights

Discovery

Pre-clinical

Candidate

SBI-101

[SIRP-Exo]

Indication

Immunotherapy resistant
solid tumor

Rights

Discovery

Pre-clinical

Candidate

SBI-102

[SIRP-Exo, MSC]

Indication

NASH with liver fibrosis
Acute Liver Failure

Rights

Discovery

Pre-clinical

Candidate

SBI-103

[EGF-Exo]

Indication

Undisclosed

Rights

Discovery

Pre-clinical

Candidate

SBI-104

[Apelin-Exo]

Indication

Pulmonary

arterial hypertension

Rights

Discovery

Pre-clinical

Candidate

SBI-205

[Exo-HIF1α]

Indication

Liver damage

Rights

Discovery

Pre-clinical

Candidate

SBI-306

[RSFV-Exo-UP]

Indication

Immunotherapy resistant
solid tumor

Rights

Discovery

Pre-clinical

Candidate

SBI-407

[Fc-Exo, MSC]

Indication

Undisclosed

Rights

Discovery

Pre-clinical

Candidate

SBI-508
 [Ag-Exo]

Indication

Immunotherapy resistant
solid tumor

Rights


Discovery

Pre-clinical

Candidate

SBI-609, LGP-S01

[ImmuNano]

Indication

Undisclosed

Rights

Discovery

Pre-clinical

Rare diseases and cancer with unmet medical needs

SHIFTBIO’s pipeline is aiming to cure orphan diseases and cancer. 

Candidate

Indication

Development Phases

Rights

Discovery

Pre-clinical

SBI-101

[SIRP-Exo]

Immunotherapy resistant
solid tumor

SBI-102

[SIRP-Exo, MSC]

NASH with liver fibrosis
Acute Liver Failure

SBI-103

[EGF-Exo]

Undisclosed

SBI-104

[Apelin-Exo]

Pulmonary
arterial hypertension

SBI-205

[Exo-HIF1α]

Liver damage

SBI-306

[RSFV-Exo-UP]

Immunotherapy resistant
solid tumor

SBI-407

[Fc-Exo, MSC]

Undisclosed

SBI-508

[Ag-Exo]

Immunotherapy resistant
solid tumor



SBI-609, LGP-S01

[ImmuNano]

Undisclosed


Candidate

Indication

2022                      2023                     2024

SBI-101

[SIRP-Exo]

Immunotherapy resistant
solid tumor

Discovery
Pre-Clinical
IND
Clinical

SBI-102

[SIRP-Exo, MSC]

NASH with liver fibrosis
Acute Liver Failure


SBI-103

[EGF-Exo]

Undisclosed


SBI-104

[Apelin-Exo]

Pulmonary
arterial hypertension

SBI-205

[Exo-HIF1α]

Liver damage


SBI-306

[RSFV-Exo-UP]

Immunotherapy resistant
solid tumor


SBI-407

[Fc-Exo, MSC]

Undisclosed

SBI-508

[Ag-Exo]

Immunotherapy resistant
solid tumor


SBI-609, LGP-S01

[ImmuNano]

Undisclosed


Candidate

Indication

2022
2023
2024~

SBI-101

[SIRP-Exo]

Immunotherapy resistant
solid tumor


Discovery


Pre-Clinical
IND
Clinical

SBI-102

[SIRP-Exo, MSC]

NASH with liver fibrosis
Acute Liver Failure

SBI-103

[EGF-Exo]

Undisclosed

Discovery
Pre-Clinical

SBI-104

[Apelin-Exo]

Pulmonary
arterial hypertension

Discovery


Pre-Clinical
IND

SBI-205

[Exo-HIF1α]

Liver damage

SBI-306

[RSFV-Exo-UP]

Immunotherapy resistant
solid tumor

Discovery

SBI-407

[Fc-Exo, MSC]

Undisclosed
Discovery
SBI-508

[Ag-Exo]

Immunotherapy resistant
solid tumor

Discovery

SBI-609, LGP-S01

[ImmuNano]

Undisclosed
Pre-Clinical
IND
Clinical